Interleukin-12 inhibits the survival of human colon cancer stem cells in vitro and their tumor initiating capacity in mice

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 92-97

  Yin, Xiao ling ^a   Wang, Ning ^a   Wei, Xing ^a   Xie, Gan feng ^a   Li, Jian jun ^a   Liang, Hou jie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Human colon cancer stem cells; Interleukin 12; Tumor initiating capacity

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 4; LENTIVIRUS VECTOR; STAT6 PROTEIN; SURVIVIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMORSPHERE FORMATION; VIRAL GENE DELIVERY SYSTEM;

ADULT; AGED; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-4; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TRANSFECTION;

MUS;

EID: 84861454595     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.015     Document Type: Article

References (39)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
2. Singh S.K., Hawkins C., Clarke I.D. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
3. O'Brien C.A., Pollett A., Gallinger S. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
4. Ricci-Vitiani L., Lombardi D.G., Pilozzi E. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
5. Huang E.H., Wicha M.S. Colon cancer stem cells: implications for prevention and therapy. Trends Mol. Med. 2008, 14:503-509.
6. Yingjie Yu, Kanwar Shailender S. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl. Oncol. 2009, 4:321-328.
7. Becker L., Huang Q., Mashimo H. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. SciWorldJ 2008, 8(November):1168-1176.
8. Dalerba Piero, Dylla Scott J., Park In-Kyung Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104(24):10158-10163.
9. + and CD133-metastatic colon cancer cells initiate tumors. J. Clin. Investig. 2008, 118(6):2011-2020.
10. Culig Z. Cytokine disbalance in common human cancers. Biochim. Biophys. Acta 2011, 1813(2):308-314.
11. Shibata Masahiko, Nezu Takeshi, Kanou Hisao, Abe Hideo, Takekawa Motoo, Fukuzawa Masahiro Decreased production of Interleukin-12 and type2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J. Clin. Gastroenterol. 2002, 34(4):416-420.
12. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T helper-type1(Th1)cells and cytotoxic lymphocytes. Blood 1994, 84:4008-4027.
13. Cebon J., Jager E., Shackleton M.J., Gibbs P., Davis I.D., Hopkins W. Two phase I studies of low dose recombinant human IL-12 with melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 2003, 3:7.
14. Duvic M., Sherman M.L., Wood G.S., Kuzel T.M., Olsen E., Foss F. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J. Am. Acad. Dermatol. 2006, 55:807.
15. Gollob J.A., Mier J.W., Veenstra K., McDermott D.F., Clancy D., Clancy M. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin. Cancer Res. 2000, 6:1678.
16. Gollob J.A., Veenstra K.G., Parker R.A., Mier J.W., McDermott D.F., Clancy D. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 2003, 21:2564.
17. Motzer R.J., Rakhit A., Schwartz L.H., Olencki T., Malone T.M., Sandstrom K. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 1998, 4:1183.
18. Motzer R.J., Rakhit A., Thompson J.A., Nemunaitis J., Murphy B.A., Ellerhorst J. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 vs. interferon-alpha 2a for patients with advanced renal cell carcinoma. J. Interferon Cytokine Res. 2001, 21:257.
19. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 2004, 22:1389.
20. Presky D.H., Yang H., Minetti L.J., Chua A.O., Nabavi N. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 1996, 93:14002-14007.
21. Airoldi I., Cocco C., Di Carlo E., Disaro S., Ognio E. Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res. 2006, 66:3978-3980.
22. Airoldi I., Di Carlo E., Cocco C., Sorrentino C., Fais F. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 2005, 106:3846-3853.
23. Airoldi I., Di Carlo E., Banelli B., Moserle L., Cocco C. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J. Clin. Invest. 2004, 113:1651-1659.
24. + T cells. Eur. J. Immunol. 2010, 40(5):1396-1407.
25. Todaro M., Alea M.P., Di Stefano A.B. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
26. Francipane M.G., Alea M.P., Lombardo Y. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res. 2008, 68:4022-4025.
27. Stefano A.B., Iovino F., Lombardo Y. Survivin is regulated by interleukin-4 in colon cancer stem cells. J. Cell. Physiol. 2010, 20:555-561.
28. + T Lymphocytes. J. Immunol. 1995, 155:111-117.
29. Ustek Duran, Durali Deniz, Aktas Esin Efficient transfection of 293T cell line with lentiviral vectors using fuGENE® Hb transfection reagent. Biochemica 2007, 3:28-29.
30. Yeung T.M., Gandhi S.C., Wilding J.L., Muschel R., Bodmer W.F. Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl. Acad. Sci. USA 2010, 107(8):3722-3727.
31. Botchkina I.L., Rowehl R.A., Rivadeneira D.E., Karpeh M.S., Crawford H., Dufour A., Ju J., Wang Y., Leyfman Y., Botchkina G.I. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics 2009, 6(1):19-29.
32. Ieta K., Tanaka F., Haraguchi N., Kita Y., Sakashita H., Mimori K., Matsumoto T., Inoue H., Kuwano H., Mori M. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann. Surg. Oncol. 2008, 15(2):638-648.
33. Jaime-Ramirez A.C., Mundy-Bosse B.L., Kondadasula S., Jones N.B., Roda J.M., Mani A., Parihar R., Karpa V., Papenfuss T.L., LaPerle K.M., Biller E., Lehman A., Chaudhury A.R., Jarjoura D., Burry R.W., Carson W.E. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN- production. J. Immunol. 2011, 186(6):3401-3409.
34. Gonzalez-Aparicio M., Alzuguren P., Mauleon I., Medina-Echeverz J., Hervas-Stubbs S., Mancheno U., Berraondo P., Crettaz J., Gonzalez-Aseguinolaza G., Prieto J., Hernandez-Alcoceba R. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 2011, 60(3):341-349.
35. + subgroups may be human small intestinal stem cells. Mol. Biol. Rep. 2011, 38(2):997-1004. (Epub 2010 June 6).
36. + population efficiently enriches colon cancer initiating cells. Ann. Surg. Oncol. 2008, 15(10):2927-2933.
37. Chen J., Liu X.S., Wang F., Xue X.C., Fang G.E., Su C.Q., Qian Q.J. Construction of a RU486 inducible recombinant adenoviral vector carrying murine interleukin-12 gene and experimental treatment of colonic carcinoma. Zhonghua Yi Xue Za Zhi 2009, 89(20):1372-1376.
38. He X.Z., Wang L., Zhang Y.Y. An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells. World J. Gastroenterol. 2008, 14(4):532-540.
39. Vermeulen L., Todaro M., de Sousa Mello F., Sprick M.R., Kemper K., Perez Alea M. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. USA 2008, 105:13427-13432.